ArTec, Inc., of Reno, Nevada announces Korean Partners and its Mission.RENO, Nev. -- ArTec, Inc., (Pink Sheets:ATKJ) announces its Korean partners includes the eminent Dr. Tai Ho Chung M.D. Ph.D., inventor of Tubercin, Mr. CC Chung (son of Dr. Tai Ho Chung) and Dr. David Chai, Ph.D. The considerable experience in medical research and pharmaceutical manufacturing will greatly enhance ArTec, Inc., accomplishing its mission. Dr. Ronald Shinn, Ph.D. is the other partner that was selected as the Chairman, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . Dr. Ronald Shinn, Ph.D. a graduate of University of California The University of California has a combined student body of more than 191,000 students, over 1,340,000 living alumni, and a combined systemwide and campus endowment of just over $7.3 billion (8th largest in the United States). at Berkely and an American citizen by birthright has been a strong advocate for the use of Tubercin to combat Cancer in the last four years. THE MISSION of ArTec is to seek US FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and South Korea FDA approvals as soon as funds are available. ArTec, Inc., is sublicensed by Shinn Capital Group, Inc., to manufacture and distribute Tubercin in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. and Canada. Tubercin is a finished product with a history of over 17 years of clinical experience in South Korea with no adverse side effects Side effects Effects of a proposed project on other parts of the firm. . What is Tubercin? Tubercin is "carbohydrate complex, which is a mixture of low molecular-weight polysaccharides of an arabinomannan structure extract from Mycobacterium tuberculosis Mycobacterium tuberculosis n. Tubercic bacillus. Mycobacterium tuberculosis , is highly effective in treating various cancer patients without incurring any adverse side effects". This was cited in the August 14, 2001 (Patent Number 6274356) US Patent Documents for public information. For further information, the US Patent and Trademark Office's Official web site is retrievable at our web site: www.artec-inc.net. Presently, Dr. Tai Ho Chung and his staff are working on a nasal spray for Tubercin. This will be an addition to the injectile administration of Tubercin. The advantages to the nasal spray are conveniences and speed of effectiveness. ArTec is pleased with the progress of the nasal spray and has samples ready for display. At this time there have been genuine proposals to make both the nasal sprays and injectiles available for humans and animals (especially pertaining to the equine family of horses). Many Grey horses contract Melanoma Cancer and Tubercin would be a desirable product for them. In addition, Arthritis affects many horses and Tubercin could be used as a pain reliever. This does not mean that other animals do not contract cancer and suffer Arthritis. Tubercin would like to explore the animal field of medicinal products. It would be premature to mention other products that involve Tubercin, such as, ointments ointments, n.pl semisolid, non–water-based treatments that are not water-soluble and that create protective films to prevent dehydration of the skin. of various kinds. We will keep you posted on our progress. Forward-looking statements in this press release, the company cautions the investors, involve risks and uncertainties pursuant to the "Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. In addition, the company cautions investors that it undertakes no obligations or responsibilities to publicly update these forward-looking statements to reflect Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion